Solventum at BofA Conference: No New Catalysts, DeepValue SELL Thesis Intact

What happened

Solventum presented at the Bank of America Global Healthcare Conference, but the transcript revealed no material new information or catalysts. The latest DeepValue report maintains a SELL rating, noting shares trade at ~191% above a DCF base of $25.39, with declining free cash flow (2024 FCF of $805M vs $1.93B in 2021) and elevated leverage (Net debt/EBITDA 4.75x). The conference appearance did not address key concerns around balance-sheet de-risking or cash flow recovery.

Implication

Investors should view the conference as a non-event that does not alter the fundamental overvaluation or financial strain. Without evidence of deleveraging or FCF recovery, the stock remains unattractive. The wide gap between market price and intrinsic value (73.88 vs 25.39) offers no margin of safety, and the absence of identified moat or catalysts leaves downside exposure high.

Thesis delta

No shift. The conference provided no updates on debt reduction, FCF trends, or operational improvements. The SELL thesis from the master report remains fully in force, with watch items (debt below 4x, rising coverage, FCF improvement) unaddressed.